Business Wire

TX-MARY-KAY

11.11.2020 02:02:04 CET | Business Wire | Press release

Share
Mary Kay Continues Its Support of Scientific Innovation and Instruction Through Educational Grants in Partnership With IMCAS Academy

Mary Kay Inc. , a decades-long pioneer and innovator in skincare research, recently provided an educational grant to the International Master Course on Aging Science (IMCAS ) Academy to fund their highly anticipated webinar on “Office Peels and Home Peels” available to plastic surgeons, dermatologists, industry specialist, and aesthetic practitioners with the goal of continuing their education and improving practice.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201110005239/en/

The webinar, which debuted worldwide to over 1,200 attendees, is just the latest event from the Academy whose mission is to provide leading education on the topic of aging science.

The webinar, moderated by IMCAS Academy Executive Editor, Dr. Dominique Du Crest, featured a renowned and diverse lineup of speakers from around the world. Mary Kay’s Dr. Michelle Hines, Director of Global Cosmetic Research & Innovation, kicked off the webinar with an overview of chemical peels and then joined experts to discuss various subjects surrounding a number of topics on the agenda. The topics covered the existential question of whether ‘to peel or not to peel’, different types of peels, peeling for darker skin types, the use of new and innovative ingredients, the dangers of peeling for patients with various skin diseases, with speakers also sharing tips on how to prolong the benefits of peeling post-procedure. The session concluded with a robust Q&A panel chaired by Dr. Uliana Gout, M.D. Alongside Dr. Hines, the featured speakers included Dr. Foteini Bageorgou, Dermatologist; Dr. Marina Landau, Dermatologist; and Dr. Mukta Sachdev, Dermatologist.

“Women of any age, anywhere in the world, want flawless skin,” said Dr. Hines. “Currently, chemical peels are a popular skin rejuvenation and skin resurfacing procedure. Professional and at-home peels offer different experiences and benefits. As there are many options available, education and awareness are important to make the best choice. Mary Kay was thrilled to provide a grant to further education and research on the topic.”

“I would like to underscore the dynamic and growing nature of our diverse community,” said Dr. Du Crest. “We have over 28,000 physician members, and with the outbreak of COVID-19, our community has expanded tremendously. Outside of our Congress, we offer webinars, sometimes twice a week, through which we create opportunities for doctors, physicians, dermatologists, and aestheticians all over the world to come together and share knowledge, expertise, and answer industry-related questions from their peers without having to travel or leave their home or office. Our e-Learning platform houses hundreds of clinical cases, numerous blog posts, over 40 webinars annually, and thousands of videos for industry professionals to be able to watch and enrich themselves on demand.”

The webinar was recorded and is available for viewing on the IMCAS Academy Library portal.

About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company 57 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com .

About International Course on Aging Science (IMCAS)
IMCAS was established in 1994 in Paris, France, as a congress dedicated to plastic surgeons and dermatologists. Since its inception, IMCAS has sought to bridge the knowledge gap between Plastic and Reconstructive Surgery and Dermatology, thereby generating synergies and helping bridge together these two fields. Its mission is to enable aesthetic practitioners to access quality scientific content on demand. IMCAS recently launched their e-learning platform, IMCAS Academy, which offers its subscribers instant access to instructional videos, scientific papers, expert interviews and more. For more information about IMCAS, click here: https://www.imcas.com/en .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release

All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release

Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye